Last reviewed · How we verify

ADHD Medication — Competitive Intelligence Brief

ADHD Medication (ADHD Medication) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Psychostimulant or non-stimulant ADHD agent. Area: Psychiatry/Neurology.

marketed Psychostimulant or non-stimulant ADHD agent Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

ADHD Medication (ADHD Medication) — Massachusetts General Hospital. ADHD medications typically work by increasing the availability of neurotransmitters like dopamine and norepinephrine in the brain to improve attention and impulse control.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ADHD Medication TARGET ADHD Medication Massachusetts General Hospital marketed Psychostimulant or non-stimulant ADHD agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Psychostimulant or non-stimulant ADHD agent class)

  1. Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ADHD Medication — Competitive Intelligence Brief. https://druglandscape.com/ci/adhd-medication. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: